Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

Apple Watch 

Takeda is testing the use of an Apple Watch app for patients with major depressive disorder (MDD).

Working with UK firm Cambridge Cognition the company is piloting the app to monitor and assess cognitive function in patients with MDD, which affects around 350 million around the world.

Nicole Mowad-Nassar, vice president of external partnerships at Takeda Pharmaceuticals USA, said: “This collaboration is part of our strategy to embrace new technology to better understand the patient experience and assist healthcare professionals in creating improved patient care pathways.”

The small 30-patient trials of adults who have been prescribed an antidepressant will evaluate the app's feasibility and compliance, and aims to understand how a wearable's measures of mood and cognition compare to traditional neuropsychological testing and patient reported assessments.

Cognition Kit's chief scientific officer Jenny Barnett said: “By combining wearable technology with world leading neuroscience, we've created an app that collects real time passive and active high-frequency mental health data.

“Being able to access data regularly from daily life can help clinical decision making. Healthcare professionals can obtain patient data and increase patient engagement in their treatment.”

To date few Apple Watch apps have been launched by pharma, with Novartis' ViaOpta app for the visually impaired being one of those that have been developed. 

The first results from the study of Takeda's Apple Watch app are due to be reported before July 2017.

2nd March 2017

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics